Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial.
Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C, Pockley AG, Blankenstein C, Hildebrandt M, Offner R, Ahrens N, Kokowski K, Hautmann M, Rödel C, Fietkau R, Lubgan D, Huber R, Hautmann H, Duell T, Molls M, Specht H, Haller B, Devecka M, Sauter A, Combs SE.
Multhoff G, et al. Among authors: molls m.
Clin Cancer Res. 2020 Oct 15;26(20):5368-5379. doi: 10.1158/1078-0432.CCR-20-1141. Epub 2020 Sep 1.
Clin Cancer Res. 2020.
PMID: 32873573
Clinical Trial.